Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Pfizer
Large Cap•1,721 Employees•IPO 1994
Current Price
₹4832.50
-79 (-1.61%)Updated
Today's Range
₹4802.00
₹4864.00
₹4832.50
52 Week Range
52W Low₹3701.00
52W High₹5993.00
₹4832.50
Downside30.57%
Upside24.01%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹23,113.35 Cr
Market Cap
Total market value of companyP/E Ratio
27.31
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
5.99
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹183.48
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
12.89%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
27.20%
ROCE
Return on Capital Employed. >15% is goodNet Margin
35.34%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
8.68%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
1.18%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
-%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.03
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹921.88
Book Value
Net asset value per shareDividend Yield
3.28%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
63.90%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
4 points- •Pfizer boasts a strong promoter holding of 63.92% as of September 2025, indicating significant confidence in the company's future prospects and stability. This high ownership stake minimizes potential risks associated with external pressures and ensures long-term strategic alignment.
- •The company exhibits a healthy Return on Equity (ROE) of 19.80% and Return on Capital Employed (ROCE) of 27.20%, suggesting efficient utilization of shareholder investments and strong operational profitability. These metrics underscore the company's ability to generate returns effectively.
Weaknesses
4 points- •Pfizer's high Price-to-Earnings (P/E) ratio of 157.00 is significantly above the sector P/E of 38.70, suggesting the stock might be overvalued relative to its earnings. This elevated valuation could pose a potential risk for investors if growth expectations are not met.
- •The company's Operating Profit Margin (OPM) stands at a negative -12.10%, indicating operational inefficiencies that need to be addressed. This negative OPM raises concerns about the company's ability to control costs and generate profit from its core operations.
Opportunities
4 points- •The pharmaceutical industry, where Pfizer operates, is poised for growth driven by increasing global healthcare expenditure, an aging population, and rising demand for innovative treatments. This provides a favorable external environment for sustained revenue expansion.
- •Growing institutional investor confidence is evident as FII holdings increased from 2.18% in March 2025 to 2.60% in September 2025, and DII holdings rose from 17.10% to 17.11% in the same period. This trend signals positive sentiment and potential for capital inflow.
Threats
4 points- •The pharmaceutical sector faces intense competition from both established players and generic drug manufacturers, potentially leading to pricing pressures and reduced market share for Pfizer. This competitive landscape demands continuous innovation and strategic differentiation.
- •Strict and evolving regulatory frameworks in the pharmaceutical industry pose a constant threat, with potential for delays in drug approvals, increased compliance costs, or adverse policy changes impacting profitability and market access for Pfizer's products.
Segment-wise Financial Analysis
Financial Results
Balance Sheet
Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format
No Balance Sheet Data Available
Standalone annual data is not available for this symbol.
Try switching to Consolidated view.
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹4987.67 | +₹155.17 | +3.21% |
| R3 | ₹4925.67 | +₹93.17 | +1.93% |
| R2 | ₹4894.83 | +₹62.33 | +1.29% |
| R1 | ₹4863.67 | +₹31.17 | +0.64% |
| PIVOT | ₹4832.83 | 0.33 | 0.01% |
| CURRENT | ₹4832.50 | - | - |
| S1 | ₹4677.67 | -₹154.83 | -3.20% |
| S2 | ₹4739.67 | -₹92.83 | -1.92% |
| S3 | ₹4770.83 | -₹61.67 | -1.28% |
| S4 | ₹4801.67 | -₹30.83 | -0.64% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-83.4% vs avg
0.11L
(02 Mar 2026)Delivery %+11.3% vs avg
57.5%
(02 Mar 2026)Avg Volume (20D)20-day average
0.67L
(03 Feb - 02 Mar)Avg Delivery %Trend ↓
46.2%
(03 Feb - 02 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Alembic Pharmaceuticals Ltd
1.42 %
Peer Comparison
| Company Name |
|---|
 Acutaas Chemicals Ltd |
 Ajanta Pharma Ltd |
 Alembic Pharmaceuticals Ltd |
 Astrazeneca Pharma India Ltd |
 Cohance Lifesciences Ltd |
 Concord Biotech Ltd |
 Emcure Pharmaceuticals Ltd |
 ERIS Lifesciences Ltd |
 Gland Pharma Ltd |
 Ipca Laboratories Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Jubilant Pharmova Ltd |
 Natco Pharma Ltd |
 Neuland Laboratories Ltd |
 Piramal Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Pfizer Ltd
Pfizer Limited is a multinational pharmaceutical company with a significant presence in India and international markets. Its core business revolves around the manufacturing, marketing, trading, and export of a wide range of pharmaceutical products. This encompasses a diverse portfolio catering to numerous therapeutic areas, reflecting a broad reach across various health conditions and patient needs.
The company's product portfolio spans a considerable number of therapeutic categories. These include treatments for neurological and central nervous system disorders (neuro/CNS), hormonal imbalances, cardiovascular diseases, haemophilia, infectious diseases (anti-infectives), gynecological conditions, pain management (analgesics), orthopedic issues, cancer (oncology), urological problems, parasitic infections, gastrointestinal disorders, respiratory illnesses, and vaccinations. Furthermore, Pfizer also offers vitamins, minerals, and nutritional supplements.
Pfizer's customer base is extensive and multifaceted. It directly serves healthcare providers, both government and private hospitals, and retail pharmacies. The company's distribution network relies on a system of independent distributors to ensure wide market reach and accessibility of its products. This distribution model allows Pfizer to effectively serve its diverse customer base across various geographical locations and healthcare settings.
In addition to its extensive product offerings, Pfizer Limited also provides internal medicine and anti-infective services directly to hospitals and nursing homes. This reflects a commitment to providing comprehensive healthcare solutions beyond just the supply of pharmaceutical products. This integrated approach strengthens its relationships with healthcare institutions and allows for more holistic patient care.
Established in 1950 and headquartered in Mumbai, India, Pfizer Limited has a long history of operation in the pharmaceutical industry. Its continued success is rooted in its diverse product portfolio, wide-ranging customer base, and established distribution network. The company's commitment to various therapeutic areas underscores its dedication to addressing a broad spectrum of healthcare needs globally.
COMPANY FACTS - PFIZER
Registered Address
The Capital, 1802 / 1901, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra East
Mumbai
MAHARASHTRA
IN
Tel: 912266932000
Website:https://www.pfizerltd.co.in/
Investor Relations:http://www.pfizerindia.com/eNewsWebsite/investor/company_profile.aspx
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,721
IPO Date: 09/12/1994
MANAGEMENT - PFIZER
Mr. Amit Agarwal
Chief Financial Officer, Executive Director - Finance
Mrs. Meenakshi Nevatia
Managing Director, Additional Executive Director
Mr. Pazhania Rengan
Additional Executive Director - Plant Operations
Ms. Shilpi Singh
Director - People Experience
Mr. Sharad Goswami
Senior Director - Policy and Public Affairs
Dr. Pankaj Gupta
Senior Director - Medical Affairs
Mr. Saral Gupta
Director - Market Access
Mr. Prashant Mahalingam
Category Lead Internal Medicine
Ms. Aditi Mehta
Category Lead - Vaccines
Dr. Manish Paliwal
Director - Regulatory Affairs
Mr. Anil Pattanshetty
Senior Director - Business Operations
Mr. Deepak Rakheja
Strategic Partnerships, Channel Development and International Neighbouring Markets Lead
Investor Questions Answered
Pfizer Ltd (PFIZER) Stock FAQs
Get answers to the most common questions about Pfizer Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Pfizer Ltd (PFIZER) is ₹4,832.5. Today, the stock has declined by ₹79.00 (1.61%), trading in a range of ₹4,802 to ₹4,864. The stock opened at ₹4,856 with a trading volume of 6,725 shares.
Pfizer Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹23,113.35 crores, P/E ratio of 27.31, ROE of 12.89%, and ROCE of 27.20%. The dividend yield stands at 3.28%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Pfizer Ltd (PFIZER) is ₹5,993, while the 52-week low is ₹3,701. Currently trading at ₹4,832.5, the stock is 49.4% away from its 52-week low and 19.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Pfizer Ltd stock at ₹4,832.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 27.31 and P/B ratio of N/A. Today's performance shows a loss of 1.61%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Pfizer Ltd offers a dividend yield of 3.28%, which means for every ₹100 invested at the current price of ₹4,832.5, you can expect to receive approximately ₹3.28 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Pfizer Ltd's key financial metrics include: P/E Ratio: 27.31, P/B Ratio: N/A, ROE: 12.89%, ROCE: 27.20%, Dividend Yield: 3.28%, EPS: ₹183.48, Book Value: ₹921.88, Debt-to-Equity: 0.03, and Current Ratio: N/A. The company's market cap stands at ₹23,113.35 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Pfizer Ltd stock opened at ₹4,856 and is currently trading at ₹4,832.5, showing a decline of ₹79.00 (1.61%). The intraday high is ₹4,864 and low is ₹4,802. The trading volume stands at 6,725 shares, indicating moderate market participation today.
Pfizer Ltd has a Price-to-Earnings (P/E) ratio of 27.31, which means investors are willing to pay ₹27.31 for every ₹1 of earnings. With an EPS of ₹183.48, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Pfizer Ltd has a market capitalization of ₹23,113.35 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹4,832.5) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Pfizer Ltd has a book value of ₹921.88 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹4,832.5, which is 424.2% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Pfizer Ltd has a Return on Equity (ROE) of 12.89% and Return on Capital Employed (ROCE) of 27.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Pfizer Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Pfizer Ltd has a debt-to-equity ratio of 0.03, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Pfizer Ltd has an Earnings Per Share (EPS) of ₹183.48, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹4,832.5 and P/E ratio of 27.31, investors are paying 27.31 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Pfizer Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Pfizer Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Pfizer Ltd stock, consider: 1) Fundamental Analysis - Review P/E (27.31), ROE (12.89%), debt-to-equity (0.03), and growth rates. 2) Technical Analysis - Check 52-week range (₹3701.00 - ₹5993.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹4832.50) with book value (₹921.88) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Pfizer Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹4,832.5 is 48225x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Pfizer Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹3701.00 - ₹5993.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.03 indicates leverage. 4) Liquidity Risk - Based on trading volume of 6,725 shares. 5) Valuation Risk - P/E of 27.31 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Pfizer Ltd operates in the industry with key metrics: P/E ratio of 27.31, ROE of 12.89%, market cap of ₹23,113.35 crores, and dividend yield of 3.28%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.03), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Pfizer Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹4,832.5, with a 52-week range of ₹3701.00 to ₹5993.00. Based on fundamentals like P/E (27.31), ROE (12.89%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Pfizer Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹4832.50. 2) Fundamental Deterioration - Declining ROE (currently 12.89%), increasing debt (D/E: 0.03), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Pfizer Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 3.28%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu